Lexeotx
Founded 2018 · 101 employees on LinkedIn · 2 known investors
LEXEO Therapeutics develops gene therapy candidates aimed at genetically mediated cardiovascular diseases and APOE4-associated Alzheimer's disease. The clinical-stage company builds on research from Weill Cornell Medicine and the University of California San Diego.
Investors · 2
Frequently asked questions
- What does Lexeotx do?
- LEXEO Therapeutics develops gene therapy candidates aimed at genetically mediated cardiovascular diseases and APOE4-associated Alzheimer's disease. The clinical-stage company builds on research from Weill Cornell Medicine and the University of California San Diego.
- Who are Lexeotx's investors?
- Lexeotx's investors include Longitude Capital, OrbiMed.